Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions

Innovating targeting

Innovating targeting

Il Consiglio Di Amministrazione approva la Posizione Finanziaria Netta relativa al Terzo Trimestre 2023

The Board of Directors approves the net financial position for the third quarter of 2023

Philogen to attend the Annual Meeting Cancéropôle Grand Sud-Ouest in Arcachon on November 22-24, 2023.

23 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

16 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Nidlegy™ ha raggiunto positivamente l’obiettivo primario dello studio di Fase III PIVOTAL in pazienti con melanoma localmente avanzato completamente resecabile (Price Sensitive)

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective in patients with locally advanced fully resectable melanoma (Price Sensitive)

09 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

02 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2023 (Price sensitive) – Courtesy English Translation

OUR SCIENCES

PIPELINE

WORK WITH US